The IPO market saw an uptick in activity this past week with six IPOs raising $919 million, led by IoT solutions developer Samsara (IOT). 14 SPACs also went public. The pipeline got a boost, with six IPOs and three SPACs submitting initial filings....read more
Bionomics, an Australian Phase 2 biotech developing allosteric ion channel modulators for CNS disorders, raised $20 million by offering 1.6 million ADSs at $12.35, below the as-converted last close of its shares on the ASX ($15.66). Insiders had indicated on...read more
Bionomics, an Australian Phase 2 biotech developing allosteric ion channel modulators for CNS disorders, announced terms for its IPO on Monday.The Eastwood, Australia-based company plans to raise $25 million by offering 1.6 million ADSs at $15.45, the...read more
US IPO Weekly Recap: 6 IPOs debut ahead of the shortened holiday week
The IPO market saw an uptick in activity this past week with six IPOs raising $919 million, led by IoT solutions developer Samsara (IOT). 14 SPACs also went public. The pipeline got a boost, with six IPOs and three SPACs submitting initial filings....read more
Australia-listed CNS biotech Bionomics prices US IPO at $12.35
Bionomics, an Australian Phase 2 biotech developing allosteric ion channel modulators for CNS disorders, raised $20 million by offering 1.6 million ADSs at $12.35, below the as-converted last close of its shares on the ASX ($15.66). Insiders had indicated on...read more
Australia-listed CNS biotech Bionomics sets terms for $25 million US IPO
Bionomics, an Australian Phase 2 biotech developing allosteric ion channel modulators for CNS disorders, announced terms for its IPO on Monday.The Eastwood, Australia-based company plans to raise $25 million by offering 1.6 million ADSs at $15.45, the...read more
US IPO Weekly Recap: The shortened holiday week brings just 1 IPO
...read more